Clovis Oncology (NASDAQ:CLVS) stock is rising 5% in early trading after Clovis’ shareholders decided to reject a proposal for a reverse split of the company’s shares. The drug maker’s shareholders ...
Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks ...
Clovis Oncology (NASDAQ:CLVS) stock is in the news Thursday as shares rocket higher thanks to positive data from a recent clinical trial. Source: CI Photos / Shutterstock.com That data comes from the ...
There’s nothing like a good old-fashioned bankruptcy warning to make a stock pop on a given day. Today, the latest speculative frenzy appears to be underway with Clovis Oncology (NASDAQ:CLVS). Shares ...
The drugmaker halted a mid-stage trial in bladder cancer patients Clovis Oncology Inc (NASDAQ:CLVS) late Friday said it was discontinuing a mid-stage trial of its lead cancer drug, rucaparib, in ...
The FDA just granted the stock's advanced prostate cancer treatment priority review status The shares of health care name Clovis Oncology Inc (NASDAQ:CLVS) are surging in electronic trading, following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results